Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
← catalyst calendarNCT06581848 · readout in 1,261 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
150estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-05 | actual | When the study began enrolling |
| Primary completion | 2030-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Intervention
- Drug: Elranatamab
Primary outcomes
what the primary-completion date above is the date OFIncidence of an adverse event (AE)/ adverse drug reaction (ADR)
measured At least 28 days from the last dose of Elranatamab
Incidence of a serious AE (SAE)/ serious ADR (SADR)
measured At least 28 days from the last dose of Elranatamab
Incidence of an unexpected AE (UAE)/ unexpected ADR (UADR)
measured At least 28 days from the last dose of Elranatamab
Incidence of a serious unexpected AE (SUAE)/ serious unexpected ADR (SUADR)
measured At least 28 days from the last dose of Elranatamab
Incidence of an adverse event special interest (AESI)
measured At least 28 days from the last dose of Elranatamab
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed